Orofar Lidocaïne Parels (Benzoxonium Chloride, Lidocaine Hydrochloride)

Benzoxonium chloride and lidocaine hydrochloride, the active ingredients in Orofar Lidocaïne Parels, are a local anesthetic and antiseptic presented as an oral formulation for mouth administration. They provide temporary numbness and antimicrobial protection for minor oral procedures in both adults and children, improving comfort during treatment.

GNH USA supplies Orofar Lidocaïne Parels as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable distribution across multiple regions globally.

Orofar Lidocaïne Parels, a combined local anesthetic and antiseptic, is used to manage oral discomfort and prevent infection in minor mucosal conditions.

- Oral mucosal irritation: provides temporary numbing and reduces microbial load - Dental procedures (e.g., scaling, minor extractions): alleviates pain during the intervention - Oral ulcerations (e.g., aphthous ulcers): eases discomfort and helps prevent secondary infection

Adverse reactions to Orofar Lidocaïne Parels are generally mild, but serious events can occur.

Common Side Effects: - Mild burning sensation in the mouth - Transient taste alteration - Mild oral irritation or redness - Nausea

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis - Severe mucosal ulceration - Systemic lidocaine toxicity (e.g., seizures, cardiac arrhythmia) - Persistent numbness beyond the application site

When using Orofar Lidocaïne Parels, consider the following precautions: - Allergy assessment: avoid use in patients with known hypersensitivity to lidocaine or benzoxonium - Age considerations: use with caution in children under two years of age - Cardiac conditions: contraindicated in patients with severe conduction disorders - Concurrent local anesthetics: limit total dose to prevent toxicity - Pregnancy and lactation: consult healthcare professional before use - Store at room temperature: keep in original container, protect from moisture and light

Potential drug interactions with Orofar Lidocaïne Parels should be reviewed before therapy.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase lidocaine plasma levels and toxicity - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic exposure

Moderate Interactions (Monitor Closely): - Other topical anesthetics: additive local anaesthetic effect - Beta‑blockers: may enhance cardiovascular depressant effects - Monoamine oxidase inhibitors: potential for increased systemic toxicity